Lee Aaron Jl, Wu Andrew Gr, Yew Kuo Chao, Shelat Vishal G
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore.
Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.
World J Gastrointest Surg. 2023 Feb 27;15(2):273-286. doi: 10.4240/wjgs.v15.i2.273.
Research on long-term survival after resection of giant (≥ 10 cm) and non-giant hepatocellular carcinoma (HCC) (< 10 cm) has produced conflicting results.
This study aimed to investigate whether oncological outcomes and safety profiles of resection differ between giant and non-giant HCC.
PubMed, MEDLINE, EMBASE, and Cochrane databases were searched. Studies designed to investigate the outcomes of giant non-giant HCC were included. The primary endpoints were overall survival (OS) and disease-free survival (DFS). The secondary endpoints were postoperative complications and mortality rates. All studies were assessed for bias using the Newcastle-Ottawa Scale.
24 retrospective cohort studies involving 23747 patients (giant = 3326; non-giant = 20421) who underwent HCC resection were included. OS was reported in 24 studies, DFS in 17 studies, 30-d mortality rate in 18 studies, postoperative complications in 15 studies, and post-hepatectomy liver failure (PHLF) in six studies. The HR was significantly lower for non-giant HCC in both OS (HR 0.53, 95%CI: 0.50-0.55, < 0.001) and DFS (HR 0.62, 95%CI: 0.58-0.84, < 0.001). No significant difference was found for 30-d mortality rate (OR 0.73, 95%CI: 0.50-1.08, = 0.116), postoperative complications (OR 0.81, 95%CI: 0.62-1.06, = 0.140), and PHLF (OR 0.81, 95%CI: 0.62-1.06, = 0.140).
Resection of giant HCC is associated with poorer long-term outcomes. The safety profile of resection was similar in both groups; however, this may have been confounded by reporting bias. HCC staging systems should account for the size differences.
关于巨大型(≥10 cm)与非巨大型肝细胞癌(HCC,<10 cm)切除术后长期生存情况的研究结果相互矛盾。
本研究旨在调查巨大型与非巨大型HCC切除术后的肿瘤学结局和安全性是否存在差异。
检索了PubMed、MEDLINE、EMBASE和Cochrane数据库。纳入旨在调查巨大型与非巨大型HCC结局的研究。主要终点为总生存期(OS)和无病生存期(DFS)。次要终点为术后并发症和死亡率。使用纽卡斯尔-渥太华量表对所有研究进行偏倚评估。
纳入了24项回顾性队列研究,共23747例接受HCC切除术的患者(巨大型=3326例;非巨大型=20421例)。24项研究报告了OS,17项研究报告了DFS,18项研究报告了30天死亡率,15项研究报告了术后并发症,6项研究报告了肝切除术后肝衰竭(PHLF)。非巨大型HCC在OS(HR 0.53,95%CI:0.50 - 0.55,<0.001)和DFS(HR 0.62,95%CI:0.58 - 0.84,<0.001)方面的HR均显著更低。30天死亡率(OR 0.73,95%CI:0.50 - 1.08,P = 0.116)、术后并发症(OR 0.81,95%CI:0.62 - 1.06,P = 0.140)和PHLF(OR 0.81,95%CI:0.62 - 1.06,P = 0.140)方面未发现显著差异。
巨大型HCC切除术后的长期结局较差。两组切除的安全性相似;然而,这可能受到报告偏倚的影响。HCC分期系统应考虑大小差异。